Full Fed. Circ. Won't Rehear Actelion Spinoff's Patent Term Bid
The full Federal Circuit has refused to revisit its decision that a company spun off from Actelion Pharmaceuticals Ltd. when it was purchased by Johnson & Johnson can't get 99 days...To view the full article, register now.
Already a subscriber? Click here to view full article